Efficient delivery of antigen to DCs using yeast-derived microparticles

Pan, Ying; Li, Xiaopeng; Kang, Tianyi; Meng, Hui; Chen, Zhouli; Yang, Li; Wu, Yang; Wei, Yuquan; Gou, Maling

doi:10.1038/srep10687

Cited by 34 publications

(31 citation statements)

References 38 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dietary supplementation with β-glucans can modulate immune function and protect against pathogen infections [ 30 , 37 , 38 ]. Similarly, recent study demonstrated that yeast-derived microparticles (mainly cell walls) induced effective immune response against tumor cells in vivo , thus stimulating both humoral and cellular immunity [ 39 ]. Consistent with that, SFY used here was more effective than HKY in immunostimulation, possibly due to its smaller particle size of cell wall components in yeasts increasing the rate and extent of absorption or interaction with the enterocytes.…”

Section: Discussionmentioning

confidence: 99%

Effects of different forms of yeast Saccharomyces cerevisiae on growth performance, intestinal development, and systemic immunity in early-weaned piglets

Jiang

Wei

Wang

et al. 2015

J Animal Sci Biotechnol

View full text Add to dashboard Cite

The present study was conducted to determine effects of different forms of yeast (Saccharomyces cerevisiae, strain Y200007) on the growth performance, intestinal development, and systemic immunity in early-weaned piglets. A total of 96 piglets (14-d old, initial average body weight of 4.5 kg) were assigned to 4 dietary treatments: (1) basal diet without yeast (Control); (2) basal diet supplemented with 3.00 g/kg live yeast (LY); (3) basal diet supplemented with 2.66 g/kg heat-killed whole yeast (HKY); and (4) basal diet supplemented with 3.00 g/kg superfine yeast powders (SFY). Diets and water were provided ad libitum to the piglets during 3-week experiment. Growth performance of piglets was measured weekly. Samples of blood and small intestine were collected at days 7 and 21 of experiment. Dietary supplementation with LY and SFY improved G:F of piglets at days 1-21 of the experiment (P < 0.05) compared to Control group. Serum concentrations of growth hormone (GH), triiodothyronine (T3), tetraiodothyronine (T4), and insulin growth factor 1 (IGF-1) in piglets at day 21 of the experiment were higher when fed diets supplemented with LY and SFY than those in Control group (P < 0.05). Compared to Control group, contents of serum urea nitrogen of piglets were reduced by the 3 yeast-supplemented diets (P < 0.05). Diets supplemented with LY increased villus height and villus-to-crypt ratio in duodenum and jejunum of piglets (P < 0.05) compared to other two groups at day 7 of the experiment. Feeding diets supplemented with LY and SFY increased (P < 0.05) serum concentrations of IgA, IL-2, and IL-6 levels in piglets compared to Control. The CD4+/CD8+ ratio and proliferation of T-lymphocytes in piglets fed diets supplemented with LY were increased compared to that of Control group at day 7 of the experiment (P < 0.05). In conclusion, dietary supplementation with both LY and SFY enhanced feed conversion, small intestinal development, and systemic immunity in early-weaned piglets, with better improvement in feed conversion by dietary supplementation with LY, while dietary supplementation with SFY was more effective in increasing systemic immune functions in early-weaned piglets.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of different forms of yeast Saccharomyces cerevisiae on growth performance, intestinal development, and systemic immunity in early-weaned piglets

Jiang

Wei

Wang

et al. 2015

J Animal Sci Biotechnol

View full text Add to dashboard Cite

show abstract

“…Capsular yeast shell microparticles were used to deliver OVA to dendritic cells. The particles are well recognized by dendritic cells and, upon internalization, trigger release of co‐stimulatory molecules . Figure and Figure show robust stimulation of humoral and cellular immune responses resulting from vaccination with antigen‐loaded glucan particles.…”

Section: Glucan‐based Drug and Vaccine Deliverymentioning

confidence: 93%

β‐glucan as a new tool in vaccine development

2019

View full text Add to dashboard Cite

Vaccination constitutes one of the major breakthroughs in human medicine. At the same time, development of more immunogenic vaccine alternatives to using aluminium-based adjuvants is one of the most important phases of vaccination development. Among different sources of carbohydrate polymers, including plants, microbes and synthetic sources tested, glucans were found to be the most promising vaccine adjuvant, as they alone stimulate various immune reactions including antibody production without any negative side effects. The use of glucan particles as a delivery system is a viable option based on the documented efficient antigen loading and receptor-targeted uptake in antigen-presenting cells. In addition to particles, soluble glucans can be used as novel hydrogels or as direct immunocyte-targeting delivery systems employing novel complexes with oligodeoxynucleotides. This review focuses on recent advances in glucan-based vaccine development from glucan-based conjugates to a glucan-based delivery and adjuvant platform.How to cite this article: Vetvicka V, Vannucci L, Sima P. β-glucan as a new tool in vaccine development. Scand J Immunol. 2020;91:e12833.

show abstract

“…One of the first examples of a supported microscale liposome was by Lee and co‐workers over two decades ago, where the authors developed a so‐called lipobead with a hydrogel as its core material . More recently, Gou and co‐workers 2–4 µm microcapsules made from yeast cells to display antigenic OVA for effective delivery to dendritic cells . To manufacture uniformly sized microscale liposomes, Deshpande and Dekker developed a high‐throughput technique to make monodisperse microscale liposomes of tunable size using microfluidics …”

Section: Microscale Materials For Immunotherapymentioning

confidence: 99%

Materials for Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell‐mediated transport and serve as artificial antigen‐presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

show abstract

Efficient delivery of antigen to DCs using yeast-derived microparticles

Cited by 34 publications

References 38 publications

Effects of different forms of yeast Saccharomyces cerevisiae on growth performance, intestinal development, and systemic immunity in early-weaned piglets

Effects of different forms of yeast Saccharomyces cerevisiae on growth performance, intestinal development, and systemic immunity in early-weaned piglets

β‐glucan as a new tool in vaccine development

Materials for Immunotherapy

Contact Info

Product

Resources

About